Is inverse probability of censoring weighting a safer choice than per-protocol analysis in clinical trials?

被引:0
|
作者
Xuan, Jingyi [1 ]
Mt-Isa, Shahrul [2 ]
Latimer, Nicholas [3 ,4 ]
Gorrod, Helen Bell [3 ]
Malbecq, William [5 ,8 ]
Vandormael, Kristel [6 ]
Yorke-Edwards, Victoria [1 ,7 ]
White, Ian R. [1 ]
机构
[1] UCL, MRC Clin Trials Unit UCL, London, England
[2] MSD, Biostat & Res Decis Sci BARDS, Hlth Technol Assessment HTA Stat, Zurich, Switzerland
[3] Univ Sheffield, Sheffield Ctr Hlth & Related Res, Sch Med & Populat Hlth, Sheffield, England
[4] Delta Hat Ltd, Nottingham, England
[5] Univ Brussels, Dept Math, Brussels, Belgium
[6] MSD, Biostat & Res Decis Sci BARDS, Hlth Technol Assessment HTA Stat, Brussels, Belgium
[7] UCL, Ctr Adv Res Comp, London, England
[8] MSD, Brussels, Belgium
基金
英国医学研究理事会;
关键词
Inverse probability of censoring weight; per-protocol; non-adherence; treatment switching; dependent censoring; MARGINAL STRUCTURAL MODELS; DIRECTED ACYCLIC GRAPHS; 2ND-LINE TREATMENT; NONCOMPLIANCE; AIDS; INTENTION; SURVIVAL; THERAPY; ISSUES; TREAT;
D O I
10.1177/09622802241289559
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Deviation from the treatment strategy under investigation occurs in many clinical trials. We term this intervention deviation. Per-protocol analyses are widely adopted to estimate a hypothetical estimand without the occurrence of intervention deviation. Per-protocol by censoring is prone to selection bias when intervention deviation is associated with time-varying confounders that also influence counterfactual outcomes. This can be corrected by inverse probability of censoring weighting, which gives extra weight to uncensored individuals who had similar prognostic characteristics to censored individuals. Such weights are computed by modelling selected covariates. Inverse probability of censoring weighting relies on the no unmeasured confounding assumption whose plausibility is not statistically testable. Suboptimal implementation of inverse probability of censoring weighting which violates the assumption will lead to bias. In a simulation study, we evaluated the performance of per-protocol and inverse probability of censoring weighting with different implementations to explore whether inverse probability of censoring weighting is a safe alternative to per-protocol. Scenarios were designed to vary intervention deviation in one or both arms with different prevalences, correlation between two confounders, effect of each confounder, and sample size. Results show that inverse probability of censoring weighting with different combinations of covariates outperforms per-protocol in most scenarios, except for an unusual case where selection bias caused by two confounders is in two directions, and 'cancels' out.
引用
收藏
页码:286 / 306
页数:21
相关论文
共 45 条
  • [1] ipcwswitch: An R package for inverse probability of censoring weighting with an application to switches in clinical trials
    Graffeo, Nathalie
    Latouche, Aurelien
    Le Tourneau, Christophe
    Chevret, Sylvie
    COMPUTERS IN BIOLOGY AND MEDICINE, 2019, 111
  • [2] Sensitivity Analysis of Per-Protocol Time-to-Event Treatment Efficacy in Randomized Clinical Trials
    Gilbert, Peter B.
    Shepherd, Bryan E.
    Hudgens, Michael G.
    JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 2013, 108 (503) : 789 - 800
  • [3] A Per-Protocol Analysis Using Inverse-Probability-of-Censoring Weights in a Randomized Trial of Initial Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor Regimens in Children
    Yin, Dwight E.
    Cole, Stephen R.
    Ludema, Christina
    Brookhart, M. Alan
    Golin, Carol E.
    Miller, William C.
    McKinney, Ross E.
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2023, 192 (06) : 916 - 928
  • [4] Interpreting the Results of Intention-to-Treat, Per-Protocol, and As-Treated Analyses of Clinical Trials
    Smith, Valerie A.
    Coffman, Cynthia J.
    Hudgens, Michael G.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (05): : 433 - 434
  • [5] Per-Protocol Versus Intention-to-Treat in Clinical Trials: The Example of GLOBAL-LEADERS Trial
    Santos-Gallego, Carlos G.
    Requena-Ibanez, Juan Antonio
    Badimon, Juan
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2022, 11 (10):
  • [6] Intent-to-Treat (ITT) vs Completer or Per-Protocol Analysis in Randomized Controlled Trials
    Andrade, Chittaranjan
    INDIAN JOURNAL OF PSYCHOLOGICAL MEDICINE, 2022, 44 (04) : 416 - 418
  • [7] Intention to treat and per protocol analysis in clinical trials
    Tripepi, Giovanni
    Chesnaye, Nicholas C.
    Dekker, Friedo W.
    Zoccali, Carmine
    Jager, Kitty J.
    NEPHROLOGY, 2020, 25 (07) : 513 - 517
  • [8] Cervical pessaries to prevent preterm birth in women with a multiple pregnancy: a per-protocol analysis of a randomized clinical trial
    Liem, Sophie M. S.
    Schuit, Ewoud
    van Pampus, Marielle G.
    van Melick, Marjo
    Monfrance, Maurice
    Langenveld, Josje
    Mol, Ben W. J.
    Bekedam, Dick
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2016, 95 (04) : 444 - 451
  • [9] When Characteristics of Clinical Trials Require Per-Protocol as Well as Intention-to-Treat Outcomes to Draw Reliable Conclusions: Three Examples
    Scheim, David E.
    Aldous, Colleen
    Osimani, Barbara
    Fordham, Edmund J.
    Hoy, Wendy E.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (11)
  • [10] Making Sense of Clinical Trial Data: Is Inverse Probability of Censoring Weighted Analysis the Answer to Crossover Bias?
    Rimawi, Mothaffar
    Hilsenbeck, Susan G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) : 453 - 458